718.15
2.96 (0.41%)
| 前收盘价格 | 715.19 |
| 收盘价格 | 716.07 |
| 成交量 | 553,987 |
| 平均成交量 (3个月) | 817,548 |
| 市值 | 78,917,509,120 |
| 市盈率 (P/E TTM) | 17.77 |
| 预期市盈率 (P/E Forward) | 15.53 |
| 价格/销量 (P/S) | 5.84 |
| 股市价格/股市净资产 (P/B) | 2.63 |
| 52周波幅 | |
| 利润日期 | 31 Jan 2025 - 4 Feb 2025 |
| 营业毛利率 | 33.61% |
| 营业利益率 (TTM) | 33.43% |
| 稀释每股收益 (EPS TTM) | 40.40 |
| 季度收入增长率 (YOY) | 10.60% |
| 季度盈利增长率 (YOY) | 33.00% |
| 总债务/股东权益 (D/E MRQ) | 9.22% |
| 流动比率 (MRQ) | 5.28 |
| 营业现金流 (OCF TTM) | 4.25 B |
| 杠杆自由现金流 (LFCF TTM) | 2.25 B |
| 资产报酬率 (ROA TTM) | 7.41% |
| 股东权益报酬率 (ROE TTM) | 17.17% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Regeneron Pharmaceuticals, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.0 |
| 价格波动 | 4.5 |
| 技术平均移动指标 | 3.5 |
| 技术振荡指标 | -2.0 |
| 平均 | 0.90 |
|
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Value |
| 内部持股比例 | 1.57% |
| 机构持股比例 | 90.66% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 1,215.00 (RBC Capital, 69.19%) | 购买 |
| 中 | 1,067.50 (48.65%) | |
| 低 | 165.00 (Canaccord Genuity, -77.02%) | 保留 |
| 平均值 | 989.88 (37.84%) | |
| 总计 | 12 购买, 3 保留, 1 卖出 | |
| 平均价格@调整类型 | 810.43 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Citigroup | 14 Jan 2025 | 795.00 (10.70%) | 保留 | 696.88 |
| 14 Nov 2024 | 895.00 (24.63%) | 保留 | 782.51 | |
| Wells Fargo | 10 Jan 2025 | 900.00 (25.32%) | 购买 | 696.88 |
| 22 Oct 2024 | 1,050.00 (46.21%) | 购买 | 962.34 | |
| Truist Securities | 08 Jan 2025 | 1,004.00 (39.80%) | 购买 | 733.59 |
| 01 Nov 2024 | 1,126.00 (56.79%) | 购买 | 843.60 | |
| Bernstein | 07 Jan 2025 | 1,070.00 (48.99%) | 购买 | 730.30 |
| Canaccord Genuity | 17 Dec 2024 | 165.00 (-77.02%) | 保留 | 740.01 |
| B of A Securities | 10 Dec 2024 | 565.00 (-21.33%) | 卖出 | 778.50 |
| Wolfe Research | 15 Nov 2024 | 1,150.00 (60.13%) | 购买 | 756.81 |
| Oppenheimer | 06 Nov 2024 | 1,000.00 (39.25%) | 购买 | 816.65 |
| BMO Capital | 01 Nov 2024 | 1,190.00 (65.70%) | 购买 | 843.60 |
| Barclays | 01 Nov 2024 | 1,065.00 (48.30%) | 购买 | 843.60 |
| 23 Oct 2024 | 1,080.00 (50.39%) | 购买 | 941.39 | |
| Morgan Stanley | 01 Nov 2024 | 1,184.00 (64.87%) | 购买 | 843.60 |
| Piper Sandler | 01 Nov 2024 | 1,195.00 (66.40%) | 购买 | 843.60 |
| RBC Capital | 01 Nov 2024 | 1,215.00 (69.18%) | 购买 | 843.60 |
| 25 Oct 2024 | 1,260.00 (75.45%) | 购买 | 933.02 | |
| Evercore ISI Group | 24 Oct 2024 | 1,175.00 (63.61%) | 购买 | 928.90 |
| JP Morgan | 24 Oct 2024 | 1,150.00 (60.13%) | 购买 | 928.90 |
| Cantor Fitzgerald | 23 Oct 2024 | 1,015.00 (41.34%) | 保留 | 941.39 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| SING GEORGE L | 715.19 | - | 166 | 118,722 |
| 累积净数量 | 166 | |||
| 累积净值 ($) | 118,722 | |||
| 累积平均购买 ($) | 715.19 | |||
| 累积平均卖出 ($) | - | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| SING GEORGE L | 董事 | 02 Jan 2025 | 获得 (+) | 166 | 715.19 | 118,722 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合